IN8bio Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

William Ho

Algemeen directeur

US$1.9m

Totale compensatie

Percentage CEO-salaris	30.8%
Dienstverband CEO	9yrs
Eigendom CEO	6.0%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is William Ho's beloning veranderd ten opzichte van IN8bio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$32m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$2m	US$572k	-US$30m
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$2m	US$550k	-US$29m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$23m
Mar 31 2022	n/a	n/a	-US$18m
Dec 31 2021	US$2m	US$446k	-US$15m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$1m	US$279k	-US$10m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$214k	US$214k	-US$6m

Compensatie versus markt: De totale vergoeding ($USD 1.85M ) William } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 483.75K ).

Compensatie versus inkomsten: De vergoeding van William is gestegen terwijl het bedrijf verliesgevend is.

CEO

William Ho (47 yo)

9yrs

Tenure

US$1,854,166

Compensatie

Mr. William Ho, also known as Will, is the Co-Founder of IN8bio, Inc. and has been President, Chief Executive Officer and Director since November 2015 and had been its Chief Financial Officer since October...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Tai-Wei Ho	Co-Founder	9yrs	US$1.85m	5.99% € 866.5k
Patrick McCall	CFO & Secretary	3.8yrs	US$914.84k	0.11% € 16.1k
Lawrence Lamb	Executive VP	6yrs	US$918.75k	0.22% € 31.3k
Kate Rochlin	Chief Operating Officer	3.9yrs	US$934.68k	0.092% € 13.3k

5.0yrs

Gemiddelde duur

44.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6JH wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Tai-Wei Ho	Co-Founder	9yrs	US$1.85m	5.99% € 866.5k
Peter Brandt	Independent Director	5.3yrs	US$195.42k	1.33% € 192.5k
Alan Roemer	Independent Chairman of the Board	4.2yrs	US$256.42k	0.61% € 88.1k
Emily Fairbairn	Independent Director	3.3yrs	US$172.92k	7.14% € 1.0m
Marcela Maus	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Travis Whitfill	Independent Director	4.2yrs	US$163.67k	0% € 0
Luba Greenwood	Independent Director	3.3yrs	US$181.42k	0.017% € 2.4k
Bruce Levine	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Siraj Ali	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Bianca Santomasso	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dieter Kabelitz	Member of Scientific Advisory board	no data	geen gegevens	geen gegevens
Michael Bishop	Member of Scientific Advisory Board	2.2yrs	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6JH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

IN8bio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

New major risk - Financial position

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

New major risk - Shareholder dilution

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

High number of new and inexperienced directors

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

High number of new and inexperienced directors

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

High number of new and inexperienced directors

High number of new and inexperienced directors

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

Independent Director recently bought €197k worth of stock

IN8bio, Inc. Provides Clinical Update from Ongoing Phase 1 Trial of INB-100

IN8bio, Inc. Appoints Kenneth R. Lamontagne as Senior Vice President, Business Development

IN8bio, Inc. Announces Positive Glioblastoma Multiforme (Gbm) Clinical Updates from the INB-200 Phase 1 Trial Presented At Asco 2022

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

IN8bio, Inc., Annual General Meeting, Jun 01, 2022

IN8bio, Inc. Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd